Cargando…

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations

Misregulation of hedgehog (Hh) signaling has been implicated in the pathogenesis of basal cell carcinoma (BCC) and medulloblastoma. Vismodegib, an orally bioavailable Hh signal pathway inhibitor targeting Smo, has been approved for the treatment of advanced BCC. However, acquired drug resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jie, Quan, Haitian, Xie, Chengying, Lou, Liguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186412/ https://www.ncbi.nlm.nih.gov/pubmed/25505589 http://dx.doi.org/10.1002/prp2.43

Ejemplares similares

The dawn of hedgehog inhibitors: Vismodegib
por: Sandhiya, Selvarajan, et al.
Publicado: (2013)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Patched Homolog 1 (PTCH1) Mutation in a CIC-Rearranged Sarcoma: Lack of Response to the Smoothened (SMO) Vismodegib
por: Wu, David J, et al.
Publicado: (2023)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Mutations in the Hedgehog Pathway Genes SMO and PTCH1 in Human Gastric Tumors
por: Wang, Xi-De, et al.
Publicado: (2013)

A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2019)

Semi‐Mechanism‐Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib
por: Lu, T, et al.
Publicado: (2015)

Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition
por: Sun, Liping, et al.
Publicado: (2014)

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants
por: Zhao, Jie, et al.
Publicado: (2014)

The histone deacetylase NlHDAC1 regulates both female and male fertility in the brown planthopper, Nilaparvata lugens
por: Zhang, Jin-Li, et al.
Publicado: (2018)

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds
por: Yang, Hyekyung, et al.
Publicado: (2015)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
por: Xie, Chengying, et al.
Publicado: (2018)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole
por: Freitas, Raíza Dias, et al.
Publicado: (2020)

Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum †
por: Diukendjieva, Antonia, et al.
Publicado: (2020)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma
por: Richtig, Georg, et al.
Publicado: (2019)

A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity
por: Wu, Xujia, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response
por: Zhao, Zhixin, et al.
Publicado: (2016)

Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
por: Hehlgans, Stephanie, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020)

Sonic Hedgehog-Induced Histone Deacetylase Activation Is Required for Cerebellar Granule Precursor Hyperplasia in Medulloblastoma
por: Lee, Seung Joon, et al.
Publicado: (2013)

SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors
por: Petroni, Marialaura, et al.
Publicado: (2019)

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance
por: Gruber, Wolfgang, et al.
Publicado: (2017)

Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms
por: Singh, Brahma N., et al.
Publicado: (2011)

Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome
por: Booms, Patrick, et al.
Publicado: (2015)

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
por: Beljkas, Milan, et al.
Publicado: (2023)

Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis
por: de Oliveira, Felipe Leite, et al.
Publicado: (2017)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

Pilomatricomas secondary to treatment with vismodegib
por: Magdaleno-Tapial, Jorge, et al.
Publicado: (2018)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Aberrant intracellular metabolism of T‐DM1 confers T‐DM1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells
por: Wang, Hongbin, et al.
Publicado: (2017)

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
por: Kalin, Jay H., et al.
Publicado: (2018)

Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
por: Bachmann, Luisa M., et al.
Publicado: (2023)

Hedgehog Inhibitors Suppress Osteoclastogenesis in In Vitro Cultures, and Deletion of Smo in Macrophage/Osteoclast Lineage Prevents Age-Related Bone Loss
por: Kohara, Yukihiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btvujvtduiiqi8jtg7i6hd2t85